Department of Global Health and Population, Harvard T H Chan School of Public Health, Boston, MA, USA.
Office of Health Equity, National Center for HIV, Viral Hepatitis, STD, and Tuberculosis Prevention, US Centers for Disease Control and Prevention, Atlanta, GA, USA.
Lancet Public Health. 2024 Aug;9(8):e564-e572. doi: 10.1016/S2468-2667(24)00151-8.
Despite an overall decline in tuberculosis incidence and mortality in the USA in the past two decades, racial and ethnic disparities in tuberculosis outcomes persist. We aimed to examine the extent to which inequalities in health and neighbourhood-level social vulnerability mediate these disparities.
We extracted data from the US National Tuberculosis Surveillance System on individuals with tuberculosis during 2011-19. Individuals with multidrug-resistant tuberculosis or missing data on race and ethnicity were excluded. We examined potential disparities in tuberculosis outcomes among US-born and non-US-born individuals and conducted a mediation analysis for groups with a higher risk of treatment incompletion (a summary outcome comprising diagnosis after death, treatment discontinuation, or death during treatment). We used sequential multiple mediation to evaluate eight potential mediators: three comorbid conditions (HIV, end-stage renal disease, and diabetes), homelessness, and four census tract-level measures (poverty, unemployment, insurance coverage, and racialised economic segregation [measured by Index of Concentration at the Extremes]). We estimated the marginal contribution of each mediator using Shapley values.
During 2011-19, 27 788 US-born individuals and 57 225 non-US-born individuals were diagnosed with active tuberculosis, of whom 27 605 and 56 253 individuals, respectively, met eligibility criteria for our analyses. We did not observe evidence of disparities in tuberculosis outcomes for non-US-born individuals by race and ethnicity. Therefore, subsequent analyses were restricted to US-born individuals. Relative to White individuals, Black and Hispanic individuals had a higher risk of not completing tuberculosis treatment (adjusted relative risk 1·27, 95% CI 1·19-1·35; 1·22, 1·11-1·33, respectively). In multiple mediator analysis, the eight measured mediators explained 67% of the disparity for Black individuals and 65% for Hispanic individuals. The biggest contributors to these disparities for Black individuals and Hispanic individuals were concomitant end-stage renal disease, concomitant HIV, census tract-level racialised economic segregation, and census tract-level poverty.
Our findings underscore the need for initiatives to reduce disparities in tuberculosis outcomes among US-born individuals, particularly in highly racially and economically polarised neighbourhoods. Mitigating the structural and environmental factors that lead to disparities in the prevalence of comorbidities and their case management should be a priority.
US Centers for Disease Control and Prevention National Center for HIV, Viral Hepatitis, STD, and Tuberculosis Prevention Epidemiologic and Economic Modeling Agreement.
尽管在过去二十年中,美国的结核病发病率和死亡率整体呈下降趋势,但结核病结局方面仍存在种族和民族差异。本研究旨在探讨健康和社区层面社会脆弱性方面的不平等在多大程度上加剧了这些差异。
我们从美国国家结核病监测系统中提取了 2011-2019 年期间结核病患者的数据。排除了耐多药结核病患者或种族和民族数据缺失的患者。我们检查了美国出生和非美国出生个体之间结核病结局的潜在差异,并对治疗完成率较高的人群(包含死亡后诊断、治疗中断或治疗期间死亡的综合结局)进行了中介分析。我们使用序贯多重中介分析评估了 8 种潜在的中介因素:3 种合并症(HIV、终末期肾病和糖尿病)、无家可归以及 4 项普查地段指标(贫困、失业、保险覆盖范围和种族经济隔离程度[用极端指数集中程度衡量])。我们使用 Shapley 值估计每个中介的边际贡献。
2011-2019 年,27788 名美国出生个体和 57225 名非美国出生个体被诊断患有活动性结核病,其中分别有 27605 人和 56253 人符合我们分析的入选标准。我们没有发现非美国出生个体的结核病结局存在种族和民族差异的证据。因此,后续分析仅限于美国出生个体。与白人个体相比,黑人和西班牙裔个体未完成结核病治疗的风险更高(校正后相对风险 1.27,95%CI 1.19-1.35;1.22,1.11-1.33)。在多中介分析中,8 种测量的中介因素解释了黑人个体差异的 67%和西班牙裔个体差异的 65%。导致黑人个体和西班牙裔个体差异的最大因素是并存的终末期肾病、并存的 HIV、普查地段层面的种族经济隔离程度以及普查地段层面的贫困程度。
本研究结果强调了美国需要采取措施减少美国出生个体结核病结局的差异,尤其是在高度种族和经济两极分化的社区。减轻导致合并症患病率及其管理方面差异的结构性和环境因素应成为优先事项。
美国疾病控制与预防中心国家艾滋病毒、病毒性肝炎、性传播疾病和结核病预防流行病学和经济建模协议。